OPBXF logo

OptiBiotix Health Plc (OPBXF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

OPBXF representa a OptiBiotix Health Plc, una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 43/100

OptiBiotix Health Plc (OPBXF) Resumen de Asistencia Médica y Tuberías

CEOStephen Patrick O'Hara
Empleados9
Sede CentralYork, GB
Año de la oferta pública inicial (OPI)2015
IndustriaBiotechnology

OptiBiotix Health Plc, a life sciences company, focuses on developing microbiome modulators for food ingredients and supplements. Their product portfolio targets chronic lifestyle diseases, offering solutions for weight management, cholesterol control, and overall wellbeing, positioning them within the competitive biotechnology sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

OptiBiotix Health Plc presents a focused investment opportunity within the microbiome modulation sector. The company's diverse product portfolio, targeting prevalent chronic diseases, offers potential for revenue growth. Key value drivers include the expansion of SlimBiome and CholBiome product lines, alongside the development of novel microbial strains. The company's gross margin of 36.5% indicates potential for profitability as revenue scales. However, the negative P/E ratio of -34.31 and a negative profit margin of -16.6% highlight existing financial challenges. Upcoming catalysts include potential partnerships and regulatory approvals for new products. Potential risks include competition from established players and the need for further funding to support research and development.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.02 billion, indicating a small-cap company with potential for growth.
  • Gross margin of 36.5%, reflecting the company's ability to generate revenue efficiently from its products.
  • Beta of 1.75, suggesting higher volatility compared to the market, which may appeal to risk-tolerant investors.
  • Focus on microbiome modulators, a growing area of interest in the healthcare and food industries.
  • Product portfolio targeting chronic lifestyle diseases, addressing a significant market need.

Competidores y Pares

Fortalezas

  • Proprietary microbiome modulation technology.
  • Diverse product portfolio targeting chronic diseases.
  • Scientific expertise and research capabilities.

Debilidades

  • Negative profitability and reliance on external funding.
  • Limited market presence compared to larger competitors.
  • Dependence on regulatory approvals for product commercialization.

Catalizadores

  • Ongoing: Expansion of SlimBiome product line into new markets.
  • Ongoing: Development of novel microbial strains for various applications.
  • Ongoing: Strategic partnerships and collaborations with food manufacturers.
  • Ongoing: Regulatory approvals for products in key markets.
  • Ongoing: Focus on personalized nutrition and tailored solutions.

Riesgos

  • Potential: Competition from established players in the biotechnology industry.
  • Potential: Regulatory changes and compliance requirements.
  • Potential: Patent expiration and intellectual property challenges.
  • Ongoing: Negative profitability and reliance on external funding.
  • Ongoing: Limited market presence compared to larger competitors.

Oportunidades de crecimiento

  • Expansion of SlimBiome Product Line: SlimBiome, a natural ingredient for weight management, presents a significant growth opportunity. The global weight management market is estimated to be worth billions of dollars, with increasing consumer demand for natural and effective solutions. OptiBiotix can leverage this trend by expanding its SlimBiome product line, targeting new markets, and developing innovative formulations. Timeline: Ongoing.
  • Development of Novel Microbial Strains: OptiBiotix's research and development efforts in identifying and developing novel microbial strains offer substantial growth potential. These strains can be used in various applications, including food ingredients, supplements, and active compounds. Successful development and commercialization of new strains can lead to increased revenue and market share. Timeline: Ongoing.
  • Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with food manufacturers, supplement companies, and pharmaceutical firms can accelerate OptiBiotix's growth. These partnerships can provide access to new markets, distribution channels, and technological expertise. Collaborations can also facilitate the development and commercialization of new products. Timeline: Ongoing.
  • Regulatory Approvals and Market Access: Obtaining regulatory approvals for its products in key markets is crucial for OptiBiotix's growth. These approvals can enhance the credibility and market acceptance of its products. Expanding market access through strategic partnerships and distribution agreements can further drive revenue growth. Timeline: Ongoing.
  • Focus on Personalized Nutrition: The growing trend of personalized nutrition presents an opportunity for OptiBiotix to develop tailored microbiome solutions for individual consumers. By leveraging data analytics and microbiome profiling, the company can create personalized products and services that address specific health needs. This approach can enhance customer engagement and loyalty. Timeline: Ongoing.

Oportunidades

  • Expanding market for microbiome-based products.
  • Strategic partnerships and collaborations.
  • Personalized nutrition and tailored solutions.

Amenazas

  • Competition from established players.
  • Regulatory changes and compliance requirements.
  • Patent expiration and intellectual property challenges.

Ventajas competitivas

  • Proprietary microbial strains and formulations.
  • Intellectual property protection through patents.
  • Scientific expertise in microbiome modulation.

Acerca de OPBXF

Founded in 2012 and headquartered in York, United Kingdom, OptiBiotix Health Plc is a life sciences company dedicated to the research and development of microbiome modulators. The company identifies and cultivates microbial strains, compounds, and formulations designed for integration into food ingredients, supplements, and active compounds. These products aim to positively influence human physiology and deliver potential health benefits. OptiBiotix's product line includes Slimbiome, a natural ingredient for weight management; SlimBiome Medical, a weight management supplement; CholBiome, a supplement for maintaining healthy cholesterol levels; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health; LPGOS, a galactooligosaccharide used in food applications to reduce cardiovascular risk factors; WellBiome, a functional fiber and mineral blend promoting gut microbiome diversity; and Sweetbiotix, a sweetener for food and beverages. The company's strategic focus is on preventing and managing chronic lifestyle diseases, such as obesity, hypercholesterolemia, and diabetes, through innovative microbiome modulation technologies.

Qué hacen

  • Researches and develops microbiome modulators.
  • Identifies and develops microbial strains.
  • Creates compounds and formulations for food ingredients.
  • Develops supplements with potential health benefits.
  • Offers solutions for weight management.
  • Provides products for maintaining healthy cholesterol levels.
  • Develops sweeteners for food and beverages.

Modelo de Negocio

  • Develops and patents proprietary microbial strains and formulations.
  • Sells ingredients and supplements to food manufacturers and consumers.
  • Generates revenue through licensing agreements and product sales.

Contexto de la Industria

OptiBiotix Health Plc operates within the biotechnology industry, specifically focusing on microbiome modulation. This sector is experiencing growth due to increasing awareness of the gut microbiome's impact on health. The competitive landscape includes companies developing probiotics, prebiotics, and other microbiome-related products. OptiBiotix differentiates itself through its focus on specific health conditions and its range of proprietary ingredients. The global microbiome market is projected to reach billions of dollars in the coming years, presenting significant opportunities for companies like OptiBiotix.

Clientes Clave

  • Food manufacturers seeking innovative ingredients.
  • Supplement companies looking to enhance their product offerings.
  • Consumers interested in natural health solutions.
Confianza de la IA: 79% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de OptiBiotix Health Plc (OPBXF): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para OPBXF.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para OPBXF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para OPBXF.

MoonshotScore

43/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de OPBXF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Stephen Patrick O'Hara

CEO

Stephen Patrick O'Hara serves as the CEO of OptiBiotix Health Plc. Information regarding his detailed background, career history, education, and previous roles is not available in the provided source data. However, as the CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the microbiome modulation sector.

Historial: Stephen Patrick O'Hara, as CEO, is responsible for guiding OptiBiotix Health Plc in its research and development of microbiome modulators. Specific achievements, strategic decisions, and company milestones under his leadership are not detailed in the provided source data. He manages a team of 9 employees.

Información del mercado OTC de OPBXF

The OTC Other tier represents the lowest tier of the OTC market, indicating that OptiBiotix Health Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. This tier typically includes companies with distressed financials, early-stage ventures, or those that choose not to comply with higher reporting standards. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like NYSE or NASDAQ.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for OPBXF is likely limited due to its OTC Other listing. Expect wider bid-ask spreads compared to exchange-listed stocks, making it potentially difficult to buy or sell shares quickly without affecting the price. Low trading volume can exacerbate these issues, leading to increased price volatility and execution risk. Investors should exercise caution and use limit orders to manage potential price slippage.
Factores de riesgo OTC:
  • Limited financial disclosure and transparency.
  • Low trading volume and liquidity.
  • Higher price volatility.
  • Potential for fraud or manipulation.
  • Lack of regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their experience.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor.
  • Check for any regulatory actions or legal issues.
Señales de legitimidad:
  • Focus on scientific research and development.
  • Development of proprietary technologies.
  • Partnerships with reputable organizations.
  • Presence of experienced management team.
  • Addresses a clear market need in microbiome modulation.

Lo Que los Inversores Preguntan Sobre OptiBiotix Health Plc (OPBXF)

¿Cuáles son los factores clave para evaluar OPBXF?

OptiBiotix Health Plc (OPBXF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Proprietary microbiome modulation technology.. Riesgo principal a monitorear: Potential: Competition from established players in the biotechnology industry.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de OPBXF?

OPBXF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de OPBXF?

Los precios de OPBXF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre OPBXF?

La cobertura de analistas para OPBXF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en OPBXF?

Las categorías de riesgo para OPBXF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established players in the biotechnology industry.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de OPBXF?

La relación P/E para OPBXF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está OPBXF sobrevalorada o infravalorada?

Determinar si OptiBiotix Health Plc (OPBXF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de OPBXF?

OptiBiotix Health Plc (OPBXF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available on CEO background and track record.
  • AI analysis pending for OPBXF.
Fuentes de datos

Popular Stocks